USANA Health Sciences Projects 2026 Net Sales of $925 Million to $1 Billion

Reuters
Jan 12
USANA Health Sciences Projects 2026 Net Sales of $925 Million to $1 Billion

USANA Health Sciences Inc. has announced its preliminary net sales results for fiscal year 2025 and issued its initial sales outlook for fiscal year 2026. For fiscal 2025, the company anticipates consolidated net sales of approximately $925 million, slightly ahead of its previous guidance of $920 million. Looking ahead to fiscal 2026, USANA projects net sales in the range of $925 million to $1.0 billion. Breaking down the outlook for 2026, the core nutritional business is expected to generate net sales between $720 million and $765 million, which is a decrease compared to the preliminary 2025 net sales of approximately $777 million. Hiya, recently acquired by USANA, is forecasted to contribute $140 million to $155 million in net sales, up from $132 million in 2025. Rise Wellness is projected to see significant growth, with expected net sales of $65 million to $80 million, a sharp increase from $16 million in 2025. The company noted that fiscal 2026 will be a 52-week year, one week shorter than fiscal 2025, impacting the core nutritional business's net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. USANA Health Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112264546) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10